Last updated on June 2019

Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer

Brief description of study

30-40% of patients who undergo radical prostatetecomy (RP) with curative intent for their localized prostate cancer experience relapse of their disease. Thus, improved therapeutic approaches are needed in this patient population. Enhancing the patient's anti-tumor immune response prior to surgery may improve long-term outcomes following RP.

Clinical Study Identifier: NCT02643667

Find a site near you

Start Over

Washington University School of Medicine

Saint Louis, MO United States
  Connect »